Hematopoietic reconstitution after bone marrow transplantation is thought to be driven by committed multipotent progenitor cells followed by long-term engrafting hematopoietic stem cells (HSCs). We observed a population of early-engrafting cells displaying HSC-like behavior, which persisted long-term in vivo in an autologous myeloablative transplant model in nonhuman primates. To identify this population, we characterized the phenotype and function of defined nonhuman primate hematopoietic stem and progenitor cell (HSPC) subsets and compared these to human HSPCs. We demonstrated that the CD34 + CD45RA
INTRODUCTION
Stringent confirmation of a hematopoietic stem cell (HSC) phenotype can only be achieved after robust long-term multilineage reconstitution of an irradiated recipient. Of the various models developed, retrovirus transduction and subsequent transplantation of CD34 + cells into human or animal recipients has permitted tracking of tens of thousands of individual cells in vivo over time (1) .
Most of these studies apply provirus insertion site analysis, which assigns the genomic locus of retrovirus integration as the clone signature. These reports generally identify successive waves of hematopoietic reconstitution after transplant wherein committed hematopoietic progenitor cells provide short-term recovery and HSCs provide long-term blood cell production, with waves of clones emerging and succeeding one another over the lifetime of the recipient (2-7). However, differences in experimental design, species studied, and the HSC definition applied have resulted in conflicting models.
Large animals such as the pig-tailed macaque (Macaca nemestrina) and the rhesus macaque (Macaca mulatta) share a close evolutionary relationship with humans and have been used as preclinical model systems to study basic HSC biology (8) or to develop specific HSC gene therapy approaches (9) . A critical advantage of these models is the ability to support both short-and long-term hematopoiesis, as well as multilineage reconstitution in an autologous, myeloablative transplant setting.
We previously used the pig-tailed macaque as a stem cell transplant model (8, 9) to study long-term hematopoietic reconstitution after transplantation of autologous lentivirus gene-modified CD34 + cells in the myeloablative setting (10) (11) (12) (13) (14) (15) (16) . Here, we wanted to examine HSC engraftment kinetics by applying a stringent definition for HSC behavior in vivo in the pig-tailed macaque transplantation model. We retrospectively followed hundreds of thousands of hematopoietic clones in five pig-tailed macaques by insertion site analysis for up to 7 years after transplantation to identify HSC behavior. We then coupled these studies with prospective, competitive transplantation and additional retrospective analyses to identify a CD34 + subpopulation capable of immediate, long-term, and stable multilineage hematopoietic reconstitution in our nonhuman primate model.
RESULTS

Persistence of early-engrafting clones up to 7.5 years after transplant
We first established the time to full, multilineage hematopoietic reconstitution in the pig-tailed macaque model by discrete analysis of hematopoietic subsets in five retrospectively transplanted animals ( fig. S1 ). We defined the day of engraftment for each lineage as the first day ≥1% fluorophore + cells were observed with consecutive increases over the next three measurements. On the basis of these data, we established the following time frames: "initial engraftment," 0 to 3 months; "stabilization," 3 months to 1 year; "homeostasis," >1 year; and "long-term" engraftment, >2 years after transplant.
To study the kinetics of individual blood cell clones in autologous CD34 + hematopoietic stem and progenitor cell (HSPC) grafts, we retrospectively analyzed the engraftment of individual lentivirus genemodified cell clones by high-throughput retrovirus insertion site analysis (Fig. 1A) . We followed 134,528 clones (range, 6830 to 43,558 unique clones per animal, n = 5) for 2 to 7.5 years after transplant (table S1) . In all five animals, clones engrafting in the first 0 to 3 months contributed more than half of the detected, gene-modified blood cells stably for >2 years after transplant (Fig. 1A) .
Early engraftment of persistent HSC clones
To deduce whether any of these early-engrafting and persistent clones displayed HSC biology in vivo, the specific clone signature (that is, genomic locus of lentivirus integration) had to be detected in multiple mature cell lineages ≥1 year after transplant and detected at additional time points. We analyzed clone signatures shared between short-lived granulocytes or monocytes and longer-lived B cells or T cells at time points ≥6 months after transplant in three of five animals (table S1) . We observed 175, 291, and 740 shared HSC clone signatures, representing 0.4, 0.9, and 2.1% of all clones detected in these animals, respectively (table S1) . We then tracked the most abundant of these HSC clone signatures over time (Fig. 1B ). Clones were characterized as "high-abundance" HSC clones if their maximum contribution over time was greater than the mean maximum contribution for all HSC clones identified in the animal. We observed abundant HSC clones within the first 6 months after transplant, which were stably maintained throughout follow-up. These data demonstrated a subpopulation of CD34 + cells with multilineage capacity that engrafted very early after autologous transplantation and was stably maintained for years in the recipient nonhuman primates. We then sought to identify such a population for targeted cellular therapy applications.
Identification of an HSC-enriched subpopulation in the nonhuman primate CD34 + cell population Self-renewal and multilineage potential are classic characteristics of HSCs. To determine which subpopulation of CD34 + cells could be HSCs, we prospectively tested the cross-reactivity of human HSPC markers with pig-tailed macaque and rhesus macaque stem cells (table S2) . Focusing on the cross-reactive markers CD34 (17, 18) , CD45RA (19) , CD90 (20) , CD117 (21) , and CD123 (22), we identified nine (I to IX) phenotypically distinct HSPC subpopulations in unmanipulated, steady-state bone marrow (ssBM), growth factor-primed bone marrow, and umbilical cord Each colored band represents one HSC clone. Bandwidth corresponds to the clone frequency (y axis). To be called an HSC clone, the clone signature (lentivirus insertion locus) had to be present in one short-lived and one long-lived mature blood cell lineage and present at more than a single time period of analysis, one of which had to be later than 1 year after transplant.
blood (Fig. 2, A and B, and fig. S2, A to D) . The average frequency of CD34 + cells in ssBM was 5.8 ± 2.9% in pig-tailed macaques and 2.2 ± 0.7% in rhesus macaques, with equal proportions of the identified subpopulations ( fig. S2 , E to G). Very low numbers of CD34 + cells were found in pigtailed macaque umbilical cord blood (0.13 ± 0.04%), but increased proportions of populations I, IV, and VII were observed ( fig. S2H ).
To evaluate self-renewal capacity, we examined the proliferation potential of defined HSPC subpopulations after flow-based sorting. All subpopulations lost CD34, CD90, and CD117 marker expression and gained CD45RA marker expression when cultured ( fig. S3A) . Population V demonstrated the greatest proliferation potential (fold expansion ≫1), followed by populations I and IV (fold expansion >1). In contrast, populations VII and VIII demonstrated no change in cell number (fold expansion ±1), and populations II, III, VI, and IX demonstrated cell loss after culture (fold expansion <1) (Fig. 2C and fig. S3B ).
We next wanted to identify which subpopulations contained HSC and multipotent progenitor cell activity and applied functional in vitro assays for differentiation of T cells ( fig. S4) S7 ). Populations I, IV, VII, and VIII were capable of generating all of the tested lineages (Fig. 2C ). Given that populations VII and VIII were more discrete subdivisions of populations I and IV, these cells were considered to be the more refined HSC/multipotent progenitor cellcontaining subpopulations.
The formation of colonies containing cobblestone area-forming cells and the ability to form secondary colonies were also suggestive of primitive, multipotent cell types (23, 24) . In the MS-5 stromal cell line coculture assay, we observed the greatest number of cells with cobblestone area-forming cell potential within population VII ( fig. S8 and table S3). In standard colony-forming cell assays, autonomous cobblestone area-forming cells from populations VII and VIII demonstrated secondary myeloid and erythroid colony-forming cell potential ( fig. S9 , A to C). Overall, secondary colony-forming cell potential was most highly enriched in population VII across all species and stem cell populations from different source tissues ( fig. S9, D 
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− HSPCs (population VIII), whereas lympho-myeloidrestricted progenitor cells were enriched in population V. Given these in vitro observations, we hypothesized that these cell fractions could contribute to the early and sustained engraftment in vivo observed in animals analyzed retrospectively. 6 cells/kg to 1.7 × 10 6 cells/kg at transplant (Fig. 3C ). Despite these low cell doses, peripheral blood absolute neutrophil counts and platelet counts rapidly rebounded in all animals within 9 to 10 and 10 to 20 days, respectively (figs. S11 and S12). Surprisingly, peripheral blood white blood cells in all animals exclusively expressed fluorophore proteins assigned to fraction i (CD34 + (fraction i) cells were exclusively responsible for multilineage cell engraftment and initial hematopoietic recovery in peripheral blood and bone marrow after autologous, myeloablative transplantation. 
. Clonal analysis demonstrated highly polyclonal engraftment with 6152 and 18,034 unique clone signatures detected for animals Z13264 and Z14004, respectively (Fig. 4) . Of these, 694 (Z13264) and 546 (Z14004) were shared clone signatures between granulocytes and B cells, and 288 (Z13264) and 662 (Z14004) were shared clone signatures between monocytes and T cells, similar to what was analyzed retrospectively in the long-term follow-up animals. In total, 1577 clone signatures (25.6% of total) were shared by two or more lineages in animal Z13264, and 1502 clone signatures (8.3% of total) were shared by two or more lineages in animal Z14004. These data confirmed that fraction i cells conferred multilineage reconstitution in vivo after transplant. Given this observation, we next wanted to determine the range of fraction i cell doses required for hematopoietic recovery after myeloablative transplant in this animal model. 
+ cell doses required for successful multilineage engraftment, we retrospectively analyzed flow cytometric data from the infusion products of 11 additional animals (table S5). Initial neutrophil engraftment (absolute neutrophil count, >500/ml) and platelet engraftment (platelets, >20,000/ml) were achieved in all animals (figs. S11 and S12). However, two animals were not able to sustain platelet and neutrophil engraftment without additional supportive care during the first 3 months after transplant ( fig. S14 ). We therefore defined these two animals as "engraftment failures" and the remaining nine animals with long-term engraftment as "engraftment successes." Animals displaying engraftment success received about sixfold the mean dose of CD34
+ cells/kg body weight compared to animals displaying engraftment failure (P = 0.019) (Fig. 5A) . No significant differences were observed among animals displaying engraftment success and failure for CD34 + , CD34 + CD45RA − CD90 − , or CD34 + CD45RA + CD90 − transplanted cells/kg body weight (Fig. 5A and fig. S15A ). Notably, we observed a strong correlation between the CD34 + CD45RA − CD90 + cell dose transplanted and the onset of neutrophil and platelet recovery in animals displaying engraftment success (Fig. 5B) (Fig. 6A) enriched a similar cell fraction in human CD34 + HSPCs, we tested our strategy on G-CSF-mobilized human peripheral blood stem cells (PBSCs) (Fig. 6B) and human umbilical cord  blood (fig. S16 ). Classical gating strategies including CD38 (20, 25) resulted in a low to moderate enrichment for CD34 + CD45RA − CD90 + cells (Fig. 6B) fig. S16 ).
Transcript expression of key molecules has been described for human HSCs (26, 27 (26, 27) in this cell population from both species (Fig. 6C and table S6 ). These data suggest phenotypic and transcriptomic similarities between human and nonhuman primate HSC-enriched cell populations, which could be biologically discriminated by expression of CD34, CD45RA, and CD90. 
+ cells to completely reconstitute hematopoiesis in the autologous, myeloablative transplant setting. We also demonstrated that limited cell doses were needed for successful hematopoietic reconstitution in this setting. The number of nonhuman primates included in the present study, validation in vivo both retrospectively and prospectively, and the tracking of individual clones to confirm these observations suggested early engraftment of HSC clones with stable contributions to hematopoiesis over time after autologous transplantation. For the fields of HSC biology and transplantation, gene therapy, and gene editing, this study identified a highly refined, small cell population capable of complete functional hematopoietic reconstitution.
These findings markedly contrast with a recent report using insertion site analysis alone to describe hematopoietic reconstitution in rhesus macaques over a decade after autologous transplantation of genemodified CD34 + cells (33) . This study identified between 846 and 5758 total clones in each of four rhesus macaques transplanted with either lentivirus-or simian immunodeficiency virus-based vector-transduced cells, which followed a biphasic reconstitution over the first year, and then sequential expansion of HSC-like clones. This study also reported that the number of clones identified in each animal was directly proportional to the CD34 + cell dose at the time of transplantation and that HSC-like clonal signatures were not observed in vivo until 7 to 9 months after transplant, gradually increasing in contribution >1 year after transplant, the time period in our study defined as homeostasis.
There are notable differences between these two studies. First, different nonhuman primate species were used for in vivo studies (rhesus macaques versus pig-tailed macaques), as well as different sources of CD34 + cells (G-CSF-mobilized leukapheresisderived CD34 + cells in rhesus macaques versus G-CSF-and stem cell factorprimed bone marrow-derived CD34 + cells in pig-tailed macaques). The fraction of repopulating HSCs declines in mobilized leukapheresis products compared to bone marrow products, with the highest proportion of HSCs found in umbilical cord blood (34) . Thus, the lower number of clones transplanted and tracked in the rhesus macaque study could reflect lower HSC content in mobilized leukapheresis products.
Additionally, there are technical differences between insertion site analysis methods used to track the clones: The rhesus macaque study used a restriction enzyme-based insertion site analysis method different from the acoustic shearing-based method that we used. Our method allowed for quality control of clone abundance by capturing different fragment sizes of the same flanking genomic sequence by single-end sequencing, whereas the rhesus macaque method relied on paired-end sequencing of resulting genomic fragments. The paired-end approach can reduce bias but also displays lower sequencing efficiency, resulting in lower clone numbers. Additionally, the rhesus macaque study collected samples from each animal a total of 7 to 12 times after transplant, over as many as 140 months, with very few samples (≤3 time points) collected within the first year. Thus, the biphasic reconstitution and clonal succession observed in the rhesus macaque study may have resulted from undersampling. A more comprehensive sampling of early time points within the first 9.5 months after transplant was reported by Wu and colleagues (35) in a side-by-side report to the rhesus macaque study. Here, the same rhesus macaque model was used (n = 3), with unique clones tracked by retrovirus DNA barcode sequencing. Monthly sampling was performed over the early reconstitution and stabilization periods we describe. Similar to our observations, cumulative clone numbers detected did not correlate with the CD34 + cell dose at time of transplant over the brief period of follow-up included in this report. This report identified multilineage clones over the first 9.5 months after transplant, beginning 2 to 3 months after infusion. Longer follow-up and additional animals will be required to demonstrate long-term persistence of these clones in the rhesus macaque model. Additionally, the DNA barcode sequencing study reported a unique ontogeny of NK cells. This analysis was not performed in our retrospective study because of lack of sorted NK cell samples. However, we observed CD34 + CD45RA − CD90 + cells contributing to the NK compartment in competitive repopulation experiments. Additional clone tracking studies will be required to confirm clonal origins of the NK lineage in our model.
Our most striking observation was that the highly HSC-enriched CD34
+ fraction accounted for all gene-modified cells observed in peripheral blood and bone marrow after transplantation in this model. This suggested that everything required for short-and longterm, multilineage hematopoietic reconstitution was contained within this cell phenotype. We observed clone signatures, which were both shared and exclusive to sorted blood cell lineages in two of the four animals studied. We also observed up to 25% of these clones shared by two or more blood cell lineages, which is a marked increase relative to animals in the retrospectively analyzed cohort. However, these studies sampled very disparate time points of follow-up in these two cohorts. Additionally, analysis in competitively repopulated animals consists of a single time point, compared to multiple time points of analysis in the retrospective cohort.
In vivo observations in competitively transplanted animals suggest that the CD34 
+ phenotype, we would expect important implications for human transplantation and gene therapy studies.
We observed a strong correlation between CD34
HSPCs/kg body weight and the success of multilineage engraftment, as well as the time to neutrophil and platelet recovery, further supporting the biological importance of our phenotypically defined, HSCenriched population. Our data demonstrate a direct correlation of a phenotypically defined HSPC subpopulation with engraftment properties after autologous transplant. We also found that the correlation between CD34 + CD45RA − CD90 + cell dose and engraftment was not affected by different stem cell sources, gene modifications, expansion protocols, or cryopreservation, making this phenotype a valuable tool for the in vitro analysis of HSC modification, expansion strategies, and quality control of stem cell infusion products. The follow-up of animals prospectively transplanted with sort-purified and fluorophore-coded subpopulations in this study is currently limited to 1 year and remains ongoing. Whereas this length of follow-up has been predictive of long-term outcome (>7 years) in our retrospective nonhuman primate studies, longer follow-up will be required to fully assess the safety and feasibility of this approach for clinical stem cell transplantation and gene therapy. Also, our evaluation of this new phenotype in human HSC sources is currently limited to phenotypic and transcriptomic analyses. Further comprehensive in vivo studies of these human HSPC subpopulations should be performed in either prospective mouse xenograft assays or retrospectively analyzed in patients if the required marker expression data and posttransplant follow-up data are available. Finally, this study did not address whether this refined HSC-enriched phenotype requires the cotransplantation of other supporting cell phenotypes.
In conclusion, retrospective detection of persistent and HSC-like clonal signatures early after transplant, before all lineages have reconstituted, suggests a subpopulation of transplanted CD34 + hematopoietic cells that immediately contributes to long-term, multilineage hematopoietic reconstitution lasting up to 7.5 years in this clinically relevant model. Most notably, using prospective transplantation studies, we have identified a subset of CD34 + cells expressing CD90 and lacking CD45RA markers, which rapidly and exclusively reconstitutes multilineage hematopoiesis at low cell doses in the autologous, myeloablative transplant setting in nonhuman primates. This cell population is similar between humans and nonhuman primates on the basis of phenotypic and transcriptomic analyses. Moreover, enumeration in the autologous setting is rapid and predictive of engraftment success and extent of supportive care required after transplant. These findings may affect HSC transplantation and the development of gene therapy and gene editing approaches.
METHODS
Study design
Retrospective insertion site analysis after autologous, myeloablative transplantation of gene-modified, CD34 + HSPCs in the nonhuman primate model suggested early, multilineage contribution of long-term engrafting blood cells. Based on these findings, the main goal of this study was to identify this subpopulation and evaluate its engraftment and differentiation potential. Combining HSPC cell surface marker expression with functional in vitro readouts, distinct HSPC subpopulations were identified in pig-tailed macaque and rhesus macaque stem cell populations from different tissue sources. Contributions of these candidate populations to short-and long-term hematopoietic recovery were tested in prospective competitive reconstitution experiments in four additional pig-tailed macaques. We longitudinally tracked the engraftment of genemodified cells in the peripheral blood and bone marrow of pig-tailed macaques by flow cytometry, functional in vitro assays, and insertion site analysis for 1 year after transplant. Correlation of HSC-enriched target cell populations with engraftment success and hematologic recovery kinetics was established with an additional 11 retrospectively transplanted animals. Finally, relevance to human hematopoiesis was studied by flow cytometry and RNA-seq, demonstrating similar cell surface marker phenotypes and transcriptomic profiles between these two species.
Cell sources, CD34 + enrichment, and in vitro culture Pig-tailed macaque ssBM, primed bone marrow, umbilical cord blood, and rhesus macaque ssBM, as well as human CD34 + cells were harvested, enriched, and cultured as previously described (11, 36) . For more details on the CD34 + enrichment, see Supplementary Methods. Enriched CD34 + cells were cultured in StemSpan (STEMCELL Technologies) supplemented with penicillin-streptomycin (100 U/ml) (Gibco by Life Technologies) and either stem cell factor (PeproTech), TPO (thrombopoietin; PeproTech), and FLT3-L (Fms-related tyrosine kinase 3 ligand; Miltenyi Biotec), or stem cell factor and IL-3 (interleukin-3; PeproTech) (100 ng/ml each).
FACS analysis and cell sorting
Antibodies used for FACS analysis and sorting of pig-tailed macaque, rhesus macaque, and human cells are listed in table S1. Dead cells and debris were excluded via forward scatter/side scatter gating. 123count eBeads (eBioscience) were used for quantification purposes. Flow cytometric analysis was performed on an LSR II (BD) and FACSAria II (BD). Cells for in vitro assays as well as autologous nonhuman primate stem cell transplants were sorted using a FACSAria II cell sorter (BD), and sort purity was assessed by recovery of sorted cells.
Functional in vitro readouts
Analysis of sort-purified pig-tailed macaque and rhesus macaque cells in functional in vitro readouts for the evaluation and quantification of erythroid, myeloid (granulocyte, monocyte/macrophage), lymphoid (T, B, and NK cells), and megakaryocytic differentiation potentials was performed as previously described (see Supplementary Methods) (37) (38) (39) .
Autologous nonhuman primate transplants and ex vivo engineering of HSPCs Autologous nonhuman primate transplants, priming (mobilization), collection of cells, and genetic engineering were conducted consistent with our previously published protocols (11) . All experimental procedures performed were reviewed and approved by the Institutional Animal Care and Use Committee of the Fred Hutchinson Cancer Research Center and University of Washington (protocol #3235-01). This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health ("The Guide"), and monkeys were randomly assigned to the study. Detailed protocols for the performed nonhuman primate transplants including (i) ex vivo engineering of HSPCs, (ii) animal housing and care, and (iii) preconditioning and supportive care can be found in Supplementary Methods.
RNA isolation, RNA quality control, RNA-seq, RNA-seq expression, and data analysis Isolation of total RNA from human and nonhuman primate bulk CD34 + cells and sort-purified HSC-enriched cell fractions was performed according to the manufacturer's instructions (see Supplementary Methods). Total RNA integrity was analyzed using an Agilent 2200 TapeStation (Agilent Technologies Inc.) and quantified using a Trinean DropSense96 spectrophotometer (Caliper Life Sciences). RNA-seq expression analysis was performed in Shared Resources at the Fred Hutchinson Cancer Research Center. Detailed protocols for data analyses can be found in Supplementary Methods. All custom R and Python codes are available on request. All other codes are publicly available and cited in the appropriate method description (see Supplementary Methods).
Insertion site analysis Detailed protocols for the insertion site analysis, persistence analysis, and determination of HSC signatures can be found in Supplementary Methods. All custom R and Python codes are available on request. All other codes are publicly available and cited in the appropriate method description (see Supplementary Methods).
Statistics
Statistical analysis of data generated from all experiments except RNAseq analysis was performed using GraphPad Prism version 5. These statistical data are presented as means ± SEM. Significance analyses were performed with the paired/unpaired, two-sided Student's t test (*P < 0.05; **P < 0.01; ***P < 0.001). Correlations were calculated using Spearman's rank correlation coefficient (correlation coefficient R 2 values of 0.0 to 0.19 = very weak, 0.20 to 0.39 = weak, 0.4 to 0.59 = moderate, 0.6 to 0.79 = strong, and 0.8 to 1.0 = very strong). Statistical analysis of RNAseq data was performed using DESeq2.
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